<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02859766</url>
  </required_header>
  <id_info>
    <org_study_id>150998-012</org_study_id>
    <nct_id>NCT02859766</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD</brief_title>
  <official_title>Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and characterize the systemic pharmacokinetics (PK) of
      free and vascular endothelial growth factor (VEGF)-bound abicipar following single and
      multiple intravitreal injections of abicipar pegol in treatment-na√Øve patients with
      neovascular age-related macular degeneration (AMD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2016</start_date>
  <completion_date type="Actual">October 20, 2017</completion_date>
  <primary_completion_date type="Actual">October 20, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Serum Concentration (CMax) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Treatment Group 1: Baseline to Week 20 and Treatment Group 2: Baseline to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Concentration Immediately before Next Dose (Ctrough) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Treatment Group 1: Baseline to Week 20 and Treatment Group 2: Baseline to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Treatment Group 1: Baseline to Week 20 and Treatment Group 2: Baseline to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Treatment Group 1: Baseline to Week 20 and Treatment Group 2: Baseline to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve from Zero to the End of the Dosing Interval &quot;tau&quot; (AUC0-tau) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Treatment Group 1: Baseline to Week 20 and Treatment Group 2: Baseline to Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve from Zero to Infinity (AUC0-inf) for Free and VEGF-Bound Abicipar</measure>
    <time_frame>Treatment Group 1: Baseline to Week 20 and Treatment Group 2: Baseline to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of Anti-abicipar Antibodies</measure>
    <time_frame>Treatment Group 1: Baseline to Week 20 and Treatment Group 2: Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment Emergent Adverse Events</measure>
    <time_frame>Treatment Group 1: Baseline to Week 20 and Treatment Group 2: Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Corrected Visual Acuity using an Eye Chart</measure>
    <time_frame>Treatment Group 1: Baseline to Week 20 and Treatment Group 2: Baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Change from Baseline in Full Ophthalmic Exam Findings [i.e. Slit Lamp Exam, Intraocular Pressure (IOP) Measurements, Funduscopic Exam]</measure>
    <time_frame>Treatment Group 1: Baseline, Week 20 and Treatment Group 2: Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in General Physical Condition as Measured through General Physical Exam</measure>
    <time_frame>Treatment Group 1: Baseline, Week 20 and Treatment Group 2: Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Changes from Baseline in Vital Signs (Blood Pressure, Pulse Rate)</measure>
    <time_frame>Treatment Group 1: Baseline, Week 20 and Treatment Group 2: Baseline, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Change from Baseline in Clinically Relevant Laboratory Values (Serum Chemistry, Hematology, Urinalysis)</measure>
    <time_frame>Treatment Group 1: Baseline, Week 20 and Treatment Group 2: Baseline, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Abicipar Pegol_Repeat Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Group 1: Abicipar pegol 2 mg administered to the study eye by intravitreal injection, 3 injections 4 weeks apart. [Day 1, Weeks 4 and 8]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abicipar Pegol_Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Group 2: Abicipar pegol 2 mg administered to the study eye by intravitreal injection on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abicipar pegol</intervention_name>
    <description>Abicipar pegol 2 mg administered to the study eye by intravitreal injection.</description>
    <arm_group_label>Abicipar Pegol_Repeat Dose</arm_group_label>
    <arm_group_label>Abicipar Pegol_Single Dose</arm_group_label>
    <other_name>AGN-150998</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Presence of active subfoveal and/or juxtafoveal choroidal neovascularization (CNV)
        secondary to age-related macular degeneration (AMD).

        Exclusion Criteria:

          -  History of or active periocular, ocular, or intraocular infection.

          -  Previous use of verteporfin photodynamic therapy (PDT) or any ocular anti-angiogenic
             therapy (eg, aflibercept, bevacizumab, ranibizumab, pegaptanib), approved or
             investigational, for the treatment of neovascular AMD or previous therapeutic
             radiation in the region.

          -  Prior use of ocular anti-VEGF agents for neovascular eye diseases other than AMD.

          -  Macular hemorrhage that involves the center of fovea in the study eye.

          -  Any prior or current systemic or ocular treatment (including surgery) for neovascular
             AMD in the study eye.

          -  Treatment with ocular corticosteroid injections or implants within 6 months in the
             study eye.

          -  History or evidence of eye surgery: Pars plana vitrectomy, Submacular surgery or other
             surgical interventions for AMD, Incisional glaucoma surgery or Cataract or refractive
             surgery within the last 3 months.

          -  AMD in the non-study eye that requires anti-VEGF treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathy Sutherland</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Win Retina</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantis Retina Institute (Atlantis Eyecare)</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobs Retina Center, Shiley Eye Institute, UCSD</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Eye Specialists Medical Group, Inc-Private Clinic</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Institute of West Florida</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialty Institute</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Florida Eye Insititute</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raj K. Maturi, MD</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye &amp; Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eyesight Ophthalmic Services, PA</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>03801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caroline Eye Associates</name>
      <address>
        <city>Southern Pines</city>
        <state>North Carolina</state>
        <zip>28387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cole Eye Institute, Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Retina Consultants</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davis Duehr Dean</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

